Autolus Therapeutics (NASDAQ:AUTL) Issues Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Autolus Therapeutics (NASDAQ:AUTL) announced its earnings results on Wednesday. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07), Zacks reports. Autolus Therapeutics had a negative net margin of 439.69% and a negative return on equity of 58.91%. The business had revenue of $21.14 million for the quarter, compared to analysts’ expectations of $21.08 million.

Autolus Therapeutics Stock Performance

Shares of AUTL opened at $1.28 on Friday. The stock has a market capitalization of $340.66 million, a PE ratio of -1.54 and a beta of 1.84. The company’s fifty day moving average is $1.50 and its 200 day moving average is $1.80. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $3.45.

Institutional Trading of Autolus Therapeutics

Several hedge funds have recently made changes to their positions in AUTL. The Manufacturers Life Insurance Company grew its position in Autolus Therapeutics by 41.6% in the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock worth $88,000 after acquiring an additional 11,289 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Autolus Therapeutics by 2,891.7% in the second quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock valued at $2,223,000 after acquiring an additional 942,540 shares during the period. UBS Group AG boosted its stake in shares of Autolus Therapeutics by 16.1% during the 3rd quarter. UBS Group AG now owns 410,662 shares of the company’s stock worth $669,000 after purchasing an additional 56,995 shares during the period. Schroder Investment Management Group raised its position in Autolus Therapeutics by 133.7% in the 3rd quarter. Schroder Investment Management Group now owns 8,433,253 shares of the company’s stock worth $13,409,000 after purchasing an additional 4,824,763 shares during the period. Finally, Marex Group plc purchased a new position in shares of Autolus Therapeutics during the second quarter valued at approximately $28,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AUTL. Needham & Company LLC reissued a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, November 3rd. Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. Wells Fargo & Company dropped their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, August 13th. Finally, William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.12.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.